FindTrial
Sign In

CD20/BCMA-directed CAR-T cells

BIOLOGICAL2 trials

Sponsors

RenJi Hospital, Huashan Hospital

Conditions

Autoimmune EncephalitisImmune-mediated Necrotizing Myopathy (IMNM)Multiple Sclerosis (MS)Myasthenia GravisNeuromyelitis Optica Spectrum Disorders (NMOSD)Stiff Person SyndromeSystemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)

Phase 1

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
RecruitingNCT06249438
RenJi HospitalImmune-mediated Necrotizing Myopathy (IMNM), Multiple Sclerosis (MS), Myasthenia Gravis +3
Start: 2024-03-20End: 2040-03-31Target: 30Updated: 2025-07-25
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
Not yet recruitingNCT07341828
Huashan HospitalAutoimmune Encephalitis, Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD) +1
Start: 2026-02-28End: 2029-02-28Target: 15Updated: 2026-01-15

Related Papers

CLINICAL IMPACT OF C-CAR168, A NOVEL ANTI-CD20/BCMA COMPOSITE AUTOLOGOUS CAR T THERAPY, IN REFRACTORY LUPUS NEPHRITIS
The Journal of Rheumatology2025-05-20